The current approach to manufacturing compounded medications is outdated and poorly optimised - failing both pharmacies and the patients they serve. Even with highly trained pharmacists and modern equipment, the process remains unnecessarily labour-intensive, prone to human error, and inconsistent in quality.
The FTC's recent letter campaign could result in prolonged litigation beyond Hatch-Waxman timelines, impacting patent validity and consumer access to generics.